Episode

Episode 500: RAS Inhibition in Pancreatic Cancer (yes this is the Uromigos podcast..)

Podcast: The Uromigos
Published: May 11, 2026
Duration seconds: 2116
Processing state: not_requested
Canonical source: https://podcasters.spotify.com/pod/show/the-uromigos/episodes/Episode-500-RAS-Inhibition-in-Pancreatic-Cancer-yes-this-is-the-Uromigos-podcast-e3j7h0g
Audio: https://anchor.fm/s/13347ea8/podcast/play/119833040/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-4-11%2F423941717-44100-2-4354664512fed.m4a
JSON: /v1/public/podcasts/the-uromigos-1214845/episodes/episode-500-ras-inhibition-in-pancreatic-cancer-yes-this-is-the-uromigos-podcast
Markdown: /podcast/the-uromigos-1214845/episode-500-ras-inhibition-in-pancreatic-cancer-yes-this-is-the-uromigos-podcast.md

Actions

POST https://stenobird.com/v1/public/podcasts/the-uromigos-1214845/episodes/episode-500-ras-inhibition-in-pancreatic-cancer-yes-this-is-the-uromigos-podcast/transcription-requests
Idempotently request low-priority transcript generation for this episode.
GET https://stenobird.com/podcast/the-uromigos-1214845/episode-500-ras-inhibition-in-pancreatic-cancer-yes-this-is-the-uromigos-podcast.md
Read the agent-friendly Markdown representation of this episode resource.

Summary

Filippo Pietrantonio from the National Cancer Institute of Milan joins the podcast to discuss the latest developments in RAS targeting in GI cancers, focusing on the exciting data with daraxonrasib in pancreatic cancer ahead of the ASCO 2026 plenary phase 3 data. We discuss the RAS pathway, prior unsuccessful targeting efforts and nuances on response and resistance.